Steven W Blue1, Andrea J Winchell1, Amy V Kaucher1, Rachel A Lieberman2, Christopher T Gilles2, Maria N Pyra3, Renee Heffron4, Xuanlin Hou5, Robert W Coombs6, Kavita Nanda7, Nicole L Davis8, Athena P Kourtis8, Joshua T Herbeck5, Jared M Baeten9, Jairam R Lingappa10, David W Erikson11. 1. Endocrine Technologies Support Core, Oregon National Primate Research Center, Beaverton, OR. 2. Shimadzu Scientific Instruments, Columbia, MD. 3. Department of Epidemiology, University of Washington, Seattle, WA. 4. Department of Epidemiology, University of Washington, Seattle, WA; Department of Global Health, University of Washington, Seattle, WA. 5. Department of Global Health, University of Washington, Seattle, WA. 6. Department of Medicine, University of Washington, Seattle, WA. 7. FHI 360, Durham, NC. 8. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA. 9. Department of Epidemiology, University of Washington, Seattle, WA; Department of Global Health, University of Washington, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA. 10. Department of Global Health, University of Washington, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA; Department of Pediatrics, University of Washington, Seattle, WA. 11. Endocrine Technologies Support Core, Oregon National Primate Research Center, Beaverton, OR. Electronic address: erikson@ohsu.edu.
Abstract
OBJECTIVE: The objective was to develop a method to simultaneously quantify five commonly used hormonal contraceptives (HCs) and two endogenous sex steroids by liquid chromatography-tandem triple quadrupole mass spectrometry (LC-MS/MS) and apply this method to human serum samples. STUDY DESIGN: We developed a method to simultaneously analyze ethinyl estradiol (EE2), etonogestrel (ENG), levonorgestrel (LNG), medroxyprogesterone acetate (MPA) and norethisterone (NET), along with estradiol (E2) and progesterone (P4), in human serum for a Shimadzu Nexera-LCMS-8050 LC-MS/MS platform. We analyzed serum collected from women self-reporting use of oral contraceptives, contraceptive implants or injectable contraceptives (n=14) and normally cycling women using no HC (n=15) as well as pooled samples from women administered various HCs (ENG, n=6; LNG, n=14; MPA, n=7; NET, n=5). RESULTS: Limits of quantitation were 0.010ng/mL for E2, EE2 and P4; 0.020ng/mL for ENG, LNG and MPA; and 0.040ng/mL for NET. Precisions for all assays, as indicated by coefficient of variation, were less than or equal to 12.1%. Accuracies for all assays were in the range of 95%-108%. Endogenous hormone values obtained from analysis of human serum samples are in agreement with levels previously reported in the literature for normally cycling women as well as for women taking the appropriate HC. CONCLUSIONS: We have developed a robust, accurate and sensitive method for simultaneously analyzing commonly used contraceptive steroids and endogenous sex steroids in human serum. IMPLICATIONS: This analytical method can be used for quantitating contraceptive steroid levels in women for monitoring systemic exposure to determine drug interactions, nonadherence, misreporting and proper dosing.
OBJECTIVE: The objective was to develop a method to simultaneously quantify five commonly used hormonal contraceptives (HCs) and two endogenous sex steroids by liquid chromatography-tandem triple quadrupole mass spectrometry (LC-MS/MS) and apply this method to human serum samples. STUDY DESIGN: We developed a method to simultaneously analyze ethinyl estradiol (EE2), etonogestrel (ENG), levonorgestrel (LNG), medroxyprogesterone acetate (MPA) and norethisterone (NET), along with estradiol (E2) and progesterone (P4), in human serum for a Shimadzu Nexera-LCMS-8050 LC-MS/MS platform. We analyzed serum collected from women self-reporting use of oral contraceptives, contraceptive implants or injectable contraceptives (n=14) and normally cycling women using no HC (n=15) as well as pooled samples from women administered various HCs (ENG, n=6; LNG, n=14; MPA, n=7; NET, n=5). RESULTS: Limits of quantitation were 0.010ng/mL for E2, EE2 and P4; 0.020ng/mL for ENG, LNG and MPA; and 0.040ng/mL for NET. Precisions for all assays, as indicated by coefficient of variation, were less than or equal to 12.1%. Accuracies for all assays were in the range of 95%-108%. Endogenous hormone values obtained from analysis of human serum samples are in agreement with levels previously reported in the literature for normally cycling women as well as for women taking the appropriate HC. CONCLUSIONS: We have developed a robust, accurate and sensitive method for simultaneously analyzing commonly used contraceptive steroids and endogenous sex steroids in human serum. IMPLICATIONS: This analytical method can be used for quantitating contraceptive steroid levels in women for monitoring systemic exposure to determine drug interactions, nonadherence, misreporting and proper dosing.
Authors: Hermes Licea-Perez; Sherry Wang; Chester L Bowen; Eric Yang Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2007-01-13 Impact factor: 3.205
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Sharon L Achilles; Felix G Mhlanga; Petina Musara; Samuel M Poloyac; Zvavahera M Chirenje; Sharon L Hillier Journal: Contraception Date: 2017-09-28 Impact factor: 3.375
Authors: Maria Pyra; Jairam R Lingappa; Renee Heffron; David W Erikson; Steven W Blue; Rena C Patel; Kavita Nanda; Helen Rees; Nelly R Mugo; Nicole L Davis; Athena P Kourtis; Jared M Baeten Journal: Contraception Date: 2018-02-17 Impact factor: 3.375
Authors: Renee Heffron; Randy Stalter; Maria Pyra; Kavita Nanda; David W Erikson; Florian Hladik; Steven W Blue; Nicole L Davis; Nelly Mugo; Athena P Kourtis; Jairam R Lingappa; Jared M Baeten Journal: AIDS Date: 2019-03-15 Impact factor: 4.177
Authors: Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Kristen M Aceves; Angelo Torres; Thomas L Cherpes Journal: Contraception Date: 2019-07-11 Impact factor: 3.375
Authors: Rena C Patel; Randy M Stalter; Katherine K Thomas; Bani Tamraz; Steven W Blue; David W Erikson; Christina J Kim; Edward J Kelly; Kavita Nanda; Athena P Kourtis; Jairam R Lingappa; Nelly Mugo; Jared M Baeten; Kimberly K Scarsi Journal: AIDS Date: 2019-11-01 Impact factor: 4.177
Authors: Leo Han; Emily Padua; Kyle D Hart; Alison Edelman; Jeffrey T Jensen Journal: Eur J Contracept Reprod Health Care Date: 2019-05-08 Impact factor: 1.848
Authors: Andrea R Thurman; Vivian Brache; Leila Cochon; Louise A Ouattara; Neelima Chandra; Terry Jacot; Nazita Yousefieh; Meredith R Clark; Melissa Peet; Homaira Hanif; Jill L Schwartz; Susan Ju; Mark A Marzinke; David W Erikson; Urvi Parikh; Betsy C Herold; Raina N Fichorova; Elizabeth Tolley; Gustavo F Doncel Journal: PLoS One Date: 2022-10-10 Impact factor: 3.752
Authors: Junmei Zhang; Chenxiao Tang; Patrick J Oberly; Margaret B Minnigh; Sharon L Achilles; Samuel M Poloyac Journal: Contraception Date: 2019-01-24 Impact factor: 3.375
Authors: Melissa J Chen; Mitchell D Creinin; David K Turok; David F Archer; Kurt T Barnhart; Carolyn L Westhoff; Michael A Thomas; Jeffrey T Jensen; Bruce Variano; Regine Sitruk-Ware; Anita Shanker; Jill Long; Diana L Blithe Journal: Contraception Date: 2020-05-19 Impact factor: 3.375